OOIR: Observatory of International Research

Papers

(The TQCC of Current Opinion in Pharmacology is 12. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-05-01 to 2026-05-01.)

Article	Citations
Recent advances in emerging PCOS therapies	134
Editorial Board	92
Corrigendum to “From “contraindicated” to “first line” – Current mechanistic insights beyond canonical β-receptor signaling” [COPHAR 76 (2024) 102458]	66
From “contraindicated” to “first line” – Current mechanistic insights beyond canonical β-receptor signaling	57
Therapeutic hurdles in acute myeloid leukemia: Leukemic stem cells, inflammation and immune dysfunction	49
The Neuro-Metabolic Epidemic and the CB1R Paradox	44
The P2X7 purinoceptor in pathogenesis and treatment of dystrophino- and sarcoglycanopathies	43
Lipid raft disruption as an opportunity for peripheral analgesia	41
The role of extracellular ATP in homeostatic immune cell migration	41
Lipidomics-driven insights into acupuncture mechanisms: From dynamic signaling networks to multi-dimensional regulations	37
Advances in pain therapeutics: Targets, mechanisms, and translational frontiers	37
Native botulinum toxin type A vs. redesigned botulinum toxins in pain: What did we learn so far?	35
Editorial Board	33
Targeting strategies and immune regulatory mechanisms of CAR-macrophages in the treatment of osteosarcoma	33
CRISPR-Cas9 in acute myeloid leukaemia: Current state-of-art and future perspectives	31
Gastrointestinal issue: Advances in gastrointestinal oncology	31
Considerations for individualized first-line systemic treatment in advanced hepatocellular carcinoma	30
Auricular stimulation therapy: An evidence-based practice strategy for depression	30
Optic nerve regeneration: Potential treatment approaches	28
Editorial overview: Special issue on “Rheumatology: Therapeutic advances for autoimmune and musculoskeletal diseases”	26
Editorial Board	26
Advanced microneedle arrays for transdermal antibiotic delivery	25
Pharmaceutical therapies targeting autophagy for the treatment of age-related macular degeneration	24
Editorial Board	24
Allogeneic double-negative T-cell therapy for acute myeloid leukemia	23

Animal models of cystic fibrosis in the era of highly effective modulator therapies	23
Innovative pipeline therapeutics in inflammatory bowel disease: Anti-tumor necrosis factor-like ligand 1A and bispecific antibodies	23
Gene therapies for RyR1-related myopathies	22
Current state of CFTR modulators for treatment of Cystic Fibrosis	22
Therapeutic approaches in different congenital myopathies	21
Riluzole in Neuroinflammation and Neurodegeneration: Mechanistic Insights and Experimental Validation	21
Targeting TRP channels for pain relief: A review of current evidence from bench to bedside	21
Oncohistone-sculpted epigenetic mechanisms in pediatric brain cancer	21
Transcutaneous electrical nerve stimulation and opioid analgesia: Exploring a potential synergistic relationship	21
Strategies to enhance anti-leukaemia immunotherapy	21
Drug development for the treatment of RyR1-related skeletal muscle diseases	20
Oligonucleotide-based therapies for cystic fibrosis	20
The role of plant-derived compounds in anti-obesity drug discovery: A molecular perspective	19
Lipids and lipid regulators in intraocular pressure homeostasis	19
Smart solutions for tough infections: The rise of next-gen transdermal drug delivery	18
Estrogen related receptor alpha: Potential modulator of age-related macular degeneration	18
NanoPhyto formulations: A promising approach for targeted therapy of gastrointestinal infections, clinical advancements, and future perspectives	17
Shaping DNA damage responses: Therapeutic potential of targeting telomeric proteins and DNA repair factors in cancer	17
Acupuncture for depression: Decoding neuroimmune crosstalk and targeting anti-inflammatory mechanisms	17
Editorial overview: “Purinergic immune cell regulation reveals novel pharmacological targets”	17
Targeting the NRF2 pathway: A promising approach for corneal endothelial dysfunction	16
Purinergic signalling in graft-versus-host disease	16
Antibiotics, the microbiome and gastrointestinal cancers: A causal interference?	16
Targeting fibroblast-like synoviocytes in rheumatoid arthritis	16
Highlighting vulnerabilities in the alternative lengthening of telomeres pathway	15
Personalizing Nutrition Therapy in Inflammatory Bowel Disease: Practical Applications and Review of the Latest Studies	15
Editorial overview: COVID-19 therapy: From lung disease to systemic disorder	15
Challenges in formulating transdermal systems for treating chronic skin infections	15
Functional role of the ER stress transducer IRE1α in CF airway epithelial inflammation	15
Revolutionizing UC monitoring: The emerging role of intestinal ultrasound	14
TMEM16A regulates MUC5AC production in airway diseases: A comprehensive review	14
TMEM16A (ANO1) as a therapeutic target in cystic fibrosis	14
Advancements in targeted therapies for acute myeloid leukemia	14
Editorial Board	13
Effects of protein glycation and protective mechanisms against glycative stress	13
Editorial overview: Introduction to the musculoskeletal section of current opinion in pharmacology	13
Novel approaches to CAR T cell target identification in acute myeloid leukemia	13
Immune dysfunction after spinal cord injury – A review of autonomic and neuroendocrine mechanisms	12
CFTR RNA- and DNA-based therapies	12
Spinal and bulbar muscular atrophy: From molecular pathogenesis to pharmacological intervention targeting skeletal muscle	12
PRRT for higher-grade neuroendocrine neoplasms: What is still acceptable?	12
AI-driven GPCR analysis, engineering, and targeting	12
Novel treatments for dry eye syndrome	12
Targeting the endocannabinoid system for the management of low back pain	12
The expanding role of split protein complementation in opsin-free optogenetics	12